Mayo Clinic Talks Pod Sleep Medicine Edition Online CME Course

Activity Description

The podcast episodes in Mayo Clinic Talks: Sleep Medicine Edition contain podcast interviews about Sleep Medicine and specifically the presentation diagnosis and management of a range of common sleep disorders. Episode topics include: The Sleepy Patient; Alternate Approaches to Obstructive Sleep Apnea; Sleep Disordered Breathing and Vascular Disease; Medications for Insomnia; Behavioral Techniques for Insomnia; Treatments for Restless Legs Syndrome; and Violent dreams, Sleep Walking and Other Strange Nighttime Events.

Target Audience

This activity is appropriate for physicians, nurse practitioners, physician assistants, residents, fellows, students and allied health professionals.

Learning Objectives

Upon conclusion of this activity, participants should be able to:

- Identify novel approaches to treating obstructive sleep apnea, their indications and effectiveness.
- Describe the relationship between sleep apnea and vascular disease
- Describe simple and effective behavioral techniques for the treatment of chronic insomnia
- Discuss appropriate first-line management for patients with restless legs syndrome
- Recognize novel pharmacologic therapies for insomnia and daytime sleepiness
- Differentiate between different causes and management of active and violent behaviors at night in patients of different ages

Attendance at this Mayo Clinic course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

Accreditation Statement



In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA

The Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals

A certificate of attendance will be provided to other healthcare professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Disclosure Summary

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Faculty, Planning Committee and Provider Disclosure Summary

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies:

Darryl S. Chutka, M.D. - Stock/Shareholder: Exact Sciences Corp

Timothy I. Morgenthatler, M.D. - Intellectual Property: Digital Oral aPPLiancE pRedictor (DOPPLER), Know-How with AR Medical Technology, Inc. Consulting Activities: Withings SA

All relevant financial relationships listed for these individuals have been mitigated.

No relevant financial relationship(s) with ineligible companies:

Bhanuprakash (Bhanu) Kolla, M.D.

Robin M. Lloyd, M.D.

Michael H. Silber, M.B., Ch.B.

Eric J. Olson, M.D.

References to off-label and/or investigational usage(s) of pharmaceuticals or instruments in their presentation and/or content:

Bhanuprakash (Bhanu) Kolla, M.D. - Generic prescription: Trazodone

Michael H. Silber, M.B., Ch.B. - Multiple: Melatonin

Michael H. Silber, M.B., Ch.B. - Multiple: Gabapentin, Pregaballin and opioids for the treatment of restless legs syndrome

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) please visit: https://ce.mayo.edu/content/disclosures.

Disclaimer

Participation in this Mayo Clinic educational activity does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course. You should be aware that substantive developments in the medical field covered by this recording may have occurred since the date of original release.

Prerequisites for Participation

There are no prerequisites needed prior to participating in this education activity.

Method of Participation

Participation in this activity consists of listening to the podcast episodes, completing multiple choice questions with an 80% pass rate, and evaluation.

How to Obtain Credit

To obtain credit, complete the assessment, evaluation and submit.

Release and Expiration Dates

Release Date: 4/18/2023 Expiration Date: 4/18/2026

Acknowledgement of Commercial Support

No commercial support was received in the production of this activity.

Faculty and Course Director Listing and Credentials

Course Director(s)
Darryl S. Chutka, M.D.

Faculty(s)
Michael H. Silber, M.B., Ch.B.
Eric J. Olson, M.D.
Timothy I. Morgenthaler, M.D.
Bhanuprakash Kolla, M.D.
Robin M. Lloyd, M.D.

Bibliographic Resources

- 1. Kushida CA, Nichols DA, Simon RD et al. Symptom-based prevalence of sleep disorders in an adult primary care population. Sleep Breathing 2000;4(1):9-14.
- 2. Davidson JR, Dickson C, Han H. Cognitive behavioral treatment for insomnia in primary care: a systematic review of sleep outcomes. Br J Gen Pract 2019; 69(686): e657–e664 doi: 10.3399/bjgp19X705065.
- 3. Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011;26:114-120.
- 4. Silber MH, Buchfuhrer MJ, Earley CJ et al. The management of restless legs syndrome: an updated algorithm. Mayo Clin Proc 2021:96:1921-1937.
- 5. Winkelman JW. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome. Sleep 2022;45: zsab212. doi: 10.1093/sleep/zsab212.
- 6. Heiser C, Steffen A, Hofauer B et al. Effect of upper airway stimulation in patients with obstructive sleep apnea (EFFECT): a randomized controlled crossover trial. J Clin Med 2021; 10, 2880. https://doi.org/10.3390/jcm10132880.
- 7. Perlis ML, Posner D, Riemann D, Bastien CH, Teel J, Thase M. Insomnia. Lancet 2022;400:1047-1060.
- 8. Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109.

Copyright

Mayo Foundation for Medical Education and Research. All rights reserved. Copyright 2022